Physician profile
George Lieb
NPI 1033171087
$87,358.00
in general payments reported to CMS, 2019-2025
48 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $17K · 2021: $12K · 2022: $9,490 · 2023: $3,113 · 2024: $7,873 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $8,942 · Travel and Lodging: $199 · Education: $77.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,600.00 |
| Food and Beverage | $8,942.46 |
| Travel and Lodging | $198.80 |
| Education | $77.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $27,346.83 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $20,116.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18,122.94 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $5,515.58 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,474.46 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $1,154.57 | 2020-2025 | Dupixent |
| Insmed, INC. | $1,149.00 | 2019-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $1,064.42 | 2019-2024 | Xarelto |
| Harmony Biosciences LLC | $948.75 | 2022-2025 | Wakix |
| Mylan Specialty L.P. | $937.15 | 2019-2024 | Yupelri |
| Genzyme Corporation | $734.65 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $471.02 | 2019-2024 | |
| United Therapeutics Corporation | $367.21 | 2019-2024 | Tyvaso |
| Grifols USA, LLC | $356.40 | 2019-2025 | Prolastin-C Liquid, Gamunex-C |
| Axsome Therapeutics, INC. | $348.95 | 2023-2025 | Sunosi |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $279.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Philips North America LLC | $241.33 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Bayer Healthcare Pharmaceuticals INC. | $198.00 | 2023-2024 | |
| Electromed, INC. | $188.91 | 2024-2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $184.48 | 2022-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $182.99 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $181.90 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $158.15 | 2019-2022 | |
| Abbvie INC. | $156.12 | 2023-2024 | |
| Celgene Corporation | $124.02 | 2019 | |
| Inspire Medical Systems, INC. | $119.75 | 2024-2025 | Inspire |
| Pfizer INC. | $100.28 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $94.75 | 2019-2021 | |
| Inogen, INC. | $94.49 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amgen INC. | $90.78 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $89.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.64 | 2019-2023 | Eliquis |
| Lilly USA, LLC | $74.33 | 2024-2025 | Zepbound |
| Nabriva Therapeutics, Plc | $72.62 | 2020-2022 | |
| Genentech USA, INC. | $70.65 | 2019 | |
| Resmed Corp | $55.11 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $52.48 | 2022-2024 | Ultomiris |
| Advanced Respiratory, INC | $45.45 | 2020 | |
| Sunovion Pharmaceuticals INC. | $45.23 | 2019 | |
| Masimo Corporation | $44.25 | 2019 | |
| Circassia INC. | $43.18 | 2019-2020 | |
| Allergan, INC. | $38.62 | 2019 | |
| Merck Sharp & Dohme LLC | $37.63 | 2022-2023 | |
| Vapotherm INC | $34.36 | 2021 | |
| Vifor Pharma, INC. | $22.85 | 2025 | Zemaira |
| Teva Pharmaceuticals USA, INC. | $18.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.43 | 2019 | |
| Gilead Sciences, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Lieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.